Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
DC CAFCFirst Claim
1. A method for managing the risk of dronedarone/beta-blocker interaction in a patient with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who is in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patient also expecting to receive a beta-blocker treatment, comprising administering dronedarone or a pharmaceutically acceptable salt thereof to said patient, and then performing the following steps:
- a—
initiating beta-blocker treatment in said patient at a low dose;
b—
and then performing a electrocardiogram (ECG) assessment in said patient; and
c—
then increasing beta-blocker dose to said patient only if results in step b) verify good tolerability.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps:
- a—initiate beta-blockers treatment at a low dose;
- b—performing a electrocardiogram (ECG) verification of good tolerability;
- c—increase of beta-blockers dose only if results in step b) are satisfying.
39 Citations
16 Claims
-
1. A method for managing the risk of dronedarone/beta-blocker interaction in a patient with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who is in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patient also expecting to receive a beta-blocker treatment, comprising administering dronedarone or a pharmaceutically acceptable salt thereof to said patient, and then performing the following steps:
-
a—
initiating beta-blocker treatment in said patient at a low dose;b—
and then performing a electrocardiogram (ECG) assessment in said patient; andc—
then increasing beta-blocker dose to said patient only if results in step b) verify good tolerability. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
Specification